The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells.
The zona pellucida (ZP), an ovarian extracellular structure, contains three major glycoproteins: ZP1, ZP2, and ZP3. A ZP3 peptide contains both an autoimmune oophoritis-inducing T cell epitope and a B cell epitope that induces autoantibody to ZP. This study investigates two major T cell costimulation pathways in this disease model. Herein we show that blockage of glycoprotein (gp)39 and CD40 interaction with gp39 monoclonal antibody (mAb) results in the failure to induce both autoimmune oophoritis and autoantibody production. Inhibition of ligand binding to the CD28 receptor with the fusion protein, murine CTLA4-immunoglobulin (Ig), also results in failure to generate antibody to ZP and significantly reduces disease severity and prevalence. Surprisingly, the frequencies of antigen-specific T cells in anti-gp39 mAb-treated mice, CTLA4-Ig treated mice, and in mice given control hamster IgG or control fusion protein L6, were equivalent as determined by limiting dilution analysis (approximately equals 1:5,000). These T cells, which produced comparable amounts of interleukin 4 and interferon gamma in vitro, were able to transfer oophoritis to normal recipients. When anti-gp39 mAb and CTLA4-Ig were given together, the effect was additive, leading to inhibition of T cell activation as determined by in vitro proliferation and limiting dilution analysis (approximately equals 1:190,000); disease and antibody responses were absent in these mice. By studying these two costimulatory pathways in parallel, we have shown that autoimmune disease and autoantibody production are inhibitable by blocking either the gp39 or the CD28 pathway, whereas inhibition of clonal expansion of the effector T cell population occurs only when both pathways are blocked.
Griggs
N D
ND
Department of Pathology, University of Virginia, Charlottesville 22908, USA.
Agersborg
S S
SS
Noelle
R J
RJ
Ledbetter
J A
JA
Linsley
P S
PS
Tung
K S
KS
D000069594:Abatacept; D000818:Animals; D000911:Antibodies, Monoclonal; D000917:Antibody Formation; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology; D001323:Autoantibodies / Q000096:biosynthesis; D018106:CD28 Antigens / Q000502:physiology*; D023201:CD40 Ligand; D060908:CTLA-4 Antigen; D002478:Cells, Cultured; D017635:Clonal Anergy; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis; D005260:Female; D018796:Immunoconjugates; D007371:Interferon-gamma / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins / Q000276:immunology / Q000502:physiology*; D051379:Mice; D008805:Mice, Inbred A; D008810:Mice, Inbred C57BL; D009869:Oophoritis / Q000276:immunology; D010053:Ovary / Q000276:immunology; D010455:Peptides / Q000737:chemistry / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D015044:Zona Pellucida / Q000276:immunology / Q000502:physiology*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D001323:Autoantibodies; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D016207:Cytokines; D018796:Immunoconjugates; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D010455:Peptides; D023201:CD40 Ligand; D000069594:Abatacept; D007371:Interferon-gamma